

EudraCT Number: 2009-017328-25

Full title of the trial: “A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer”

The PACOVAR trial was planned as a Phase I/II study. Phase I was conducted properly and 16 patients were enrolled. After completion of Phase I, the data were evaluated and it was decided to terminate the study prematurely as the investigational product had not established itself for the indication. The data obtained in Phase I have been published. The publication can be accessed via the following link:

Gynecologic Oncology 146 (2017) 279–284. doi: 10.1016/j.ygyno.2017.05.013  
<https://www.sciencedirect.com/science/article/pii/S0090825817308521?via%3Dihub>